INFLAMMATION

Pharmidex provides high quality contract research services to progress compounds from hit identification through to lead optimisation in gastrointestinal disease models such as inflammatory bowel disease (Ulcerative Colitis, Crohn’s disease and fibrosis).


We combine our specialist expertise across the different disciplines to provide PK, PD, target engagement and efficacy information for client’s candidate therapeutics and have a track record of progressing clients candidate therapeutics through to clinical evaluation in this area.

Inflammatory Disease Services

The range of primary in vivo assays/models provided includes:

  • Ulcerative colitis models (DSS or TNBS-induced in preclinical species)


  • Intestinal fibrosis (DSS or TNBS-induced in preclinical species)

Gastrointestinal Disease

IBD are a group of chronic inflammatory conditions affecting the small or large intestine, of which Crohn’s and ulcerative colitis two most prevalent conditions. These put a huge burden on individuals and society alike, as the unmet medical need in this area remains significant.


Pharmidex is committed to supporting industry and academic partners in their search for developing safer and more efficacious treatment for IBD.

We offer our drug development expertise in IBD therapeutics and provide a research service, including pharmacodynamic assays and translatable IBD models, in addition to bioanalysis.

Inflammatory Bowel Disease

Areas of Expertise

  • The company has over 22 years experience in the field of offering translatable inflammatory disease models to the pharma/biotech industry


  • We have a variety of robust and fully validated models for gastrointestinal disease such as Ulcerative Colitis and Crohn’s disease

We have a track record with compounds reaching clinical evaluation in this therapeutic area.

Share by: